Novobiocin
- Generic Name
- Novobiocin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H36N2O11
- CAS Number
- 303-81-1
- Unique Ingredient Identifier
- 17EC19951N
- Background
Novobiocin is an antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189)
Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964 and was indicated for the treatment of serious infections due to susceptible strains of Staphylococcus aureus when other less toxic antibiotics cannot be used. In 2009, the FDA determined novobiocin sodium was withdrawn from sale for reasons of safety or effectiveness.
- Indication
⑴抗菌谱和青霉素相似，主要用于耐药性金葡菌引起的感染，如肺炎、败血症等，对严重感染疗效较差。易引起细菌耐药性，故宜和其他抗菌药物配伍应用。
⑵由于本品对DNA回旋酶有很好的抑制作用，对多种癌细胞有抑制作用，并能与抗癌药联合应用，逆转抗癌药的耐药性。
- Associated Conditions
- -
- Associated Therapies
- -
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- Conditions
- Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Diagnostic ImagingBiological: Novobiocin Sodium
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT05687110
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.